LXEO

Lexeo Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 4/10
  • Value↑ 5/10
Lexeo Therapeutics sales and earnings growth
LXEO Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -115.39%
  • FCF Y/Y↓ -59.15%
Lexeo Therapeutics gross and profit margin trends
LXEO Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Lexeo Therapeutics net debt vs free cash flow
LXEO Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -998.7

Lexeo Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗